SCHEDULE: Armistice Capital Discloses 4.99% Stake in Acurx Pharma

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a 4.99% beneficial ownership stake in Acurx Pharmaceuticals, Inc.

Summary

• Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 83,233 shares of Acurx Pharmaceuticals, Inc. common stock.
• This represents 4.99% of the company's outstanding common stock.
• The shares are held with shared voting and shared dispositive power by both reporting persons.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd is the managing member of Armistice Capital, LLC.
• The filing indicates the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: A Schedule 13G filing is a neutral disclosure of beneficial ownership. It indicates an institutional investor holds a stake but does not provide operational or financial performance data to assess positive or negative sentiment beyond the fact of the investment itself.

Positives

• Institutional investment by Armistice Capital, LLC and Steven Boyd indicates a level of confidence in Acurx Pharmaceuticals, Inc.
• The stake is below the 5% threshold, suggesting a passive investment strategy without immediate intent to influence control.

Negatives

• The filing itself does not present any negative financial or operational information about Acurx Pharmaceuticals, Inc.

Risks

• The filing does not detail specific risks related to Acurx Pharmaceuticals, Inc.'s operations or financial health. It only states the nature of the investment.

Future Outlook

Not applicable as this filing is an ownership disclosure and does not contain forward-looking statements or guidance from the issuer.

Industry Context

This filing reflects a standard institutional investment disclosure in the pharmaceutical/biotech sector. Investment firms like Armistice Capital frequently take passive stakes in public companies, signaling their belief in the company's long-term prospects without seeking active management roles.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can be viewed positively as a vote of confidence.
• Management: Awareness of a significant passive investor on the shareholder register.

Key Dates

Keywords

Acurx Pharmaceuticals, Armistice Capital, Steven Boyd, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Investor, Pharmaceuticals, Biotech